Systemic Amyloidosis Market Report 2025 (Global Edition)

Global Systemic Amyloidosis Market Report 2025 Market Size Split by Type (Primary systemic amyloidosis (PSA), Amyloidosis associated with multiple myeloma, Secondary systemic amyloidosis, Others), by ...

Systemic Amyloidosis Market Report Description

We have various report editions of Systemic Amyloidosis Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Systemic Amyloidosis Market Insights Video

Competitive Landscape of the Systemic Amyloidosis Market

A combination of pharmaceutical corporations, biotechnology businesses, and research institutions make up the competitive landscape of the global market for systemic amyloidosis. Leading companies in the development of cutting-edge treatments for amyloidosis include Pfizer Inc., Takeda Pharmaceutical Company Limited, and Alnylam Pharmaceuticals Inc. These companies are actively involved in research partnerships and clinical studies to expand therapy choices. In addition, research and academic institutions are essential to expanding our knowledge of amyloidosis and creating possible treatments. The race to provide patients with viable treatments drives the competitive dynamics in the systemic amyloidosis market, considering the significant unmet medical need for amyloidosis.

January 2021: For newly diagnosed systemic amyloidosis, Janssen Biotech announced that the Food and Drug Administration has approved daratumumab with hyaluronidase in combination with bortezomib, dexamethasone, and cyclophosphamide. Updated positive results from the Phase III ANDROMEDA study, which is testing hyaluronidase and daratumumab for the diagnosis of people with newly diagnosed systemic amyloidosis—a rare blood cell disorder associated with the decline of vital organs, most notably the liver, heart, and kidneys—have been released. (Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis ) January 2019: Alexion Pharmaceuticals, Inc. and Caelum Biosciences announced a collaboration to investigate CAEL-101 for systemic amyloidosis—First-in-class and specifically designed to attack amyloid fibrils. The goal of CAEL-101 is to reduce or eliminate amyloid deposits in order to improve organ function in people with systemic amyloidosis. They believe that CAEL-101 will be very beneficial to these patients, and they are excited to have it in their growing pipeline of clinical-stage uncommon hematological medications. (Source: https://media.alexion.com/news-releases/news-release-details/alexion-and-caelum-biosciences-announce-collaboration-develop )

Top Companies Market Share in Systemic Amyloidosis Industry: (In no particular order of Rank)

• Pfizer Inc
• Celgene Corporation(Bristol-Myers Squibb)
• Prothena Corporation PLC
• Takeda Pharmaceutical Company Limited
• TheraPharm Deutschland GmbH
• Johnson & Johnson
• Amgen Inc
• GlaxoSmithKline plc
• Alnylam Pharmaceuticals Inc
• Onclave Therapeutics Limited
• Allergan plc
• AbbVie Inc
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Systemic Amyloidosis Market

Which Region Dominates the Systemic Amyloidosis Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue propelled by strong consumer awareness, a robust healthcare infrastructure, and technological breakthroughs. To stay at the top of the market, major businesses in the area prioritize product differentiation and innovation. Moreover, the potential release of pharmaceuticals from the pipeline spurred the acceptance of novel medicines, and the high cost of healthcare in the US is another major factor contributing to their dominant systemic amyloidosis market share.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Systemic Amyloidosis market driven by growing access to healthcare, rising disposable incomes, and fast urbanization. The main focuses of systemic amyloidosis market expansion strategies include R&D expenditures, strategic alliances, and product localization. Moreover, because of increasing investment, better healthcare infrastructure, and supportive government policies, emerging markets for systemic amyloidosis, like China and India, are anticipated to see promising growth over the projection period.

The current report Scope analyzes Systemic Amyloidosis Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Systemic Amyloidosis

P>According to Cognitive Market Research, the global systemic amyloidosis market size was estimated at USD 4256.5 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1702.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the systemic amyloidosis market with a market size of USD 1343.35 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period because of more financing, better infrastructure, and supportive government programs for the healthcare industry.
• The Canada systemic amyloidosis market had a market share of USD 204.31 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period as a result of increased efforts being put into development and research.
• The Mexico systemic amyloidosis market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 154.94 million in 2024.

Europe Systemic Amyloidosis

According to Cognitive Market Research, the global systemic amyloidosis market size was estimated at USD 4256.5 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 1276.95 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

• The United Kingdom systemic amyloidosis market had a market share of USD 214.53 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period due of government programs that are supportive, increased funding, and improved infrastructure for the healthcare sector.
• The France systemic amyloidosis market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 117.48 million in 2024.
• According to Cognitive Market Research, the German systemic amyloidosis market size was valued at USD 252.84 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period as a result of more efforts being made in research and development.
• The Italy systemic amyloidosis market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 109.82 million in 2024.
• The Russia systemic amyloidosis market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 197.93 million in 2024.
• The Spain systemic amyloidosis market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 104.71 million in 2024
• The Luxembourg systemic amyloidosis market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 39.59 million in 2024.
• The Portugal systemic amyloidosis market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 26.82 million in 2024.
• The Greece systemic amyloidosis market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 15.32 million in 2024.
• Rest of Europe's systemic amyloidosis market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 197.93 million in 2024.

Asia Pacific Systemic Amyloidosis

According to Cognitive Market Research, the global systemic amyloidosis market size was estimated at USD 4256.5 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 979.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.

• According to Cognitive Market Research, the China systemic amyloidosis market size was valued at USD 440.55 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period due to advancements in the field of medicine.
• The Japan systemic amyloidosis market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 135.10 million in 2024.
• The India systemic amyloidosis market had a market share of USD 117.48 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period due to the increasing age of the population.
• The South Korean systemic amyloidosis market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 97.90 million in 2024.
• The Australian systemic amyloidosis market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 50.91 million in 2024.
• The South East Asia systemic amyloidosis market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 67.55 million in 2024.
• The Rest of Asia Pacific systemic amyloidosis market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 69.51 million in 2024.

South America Systemic Amyloidosis

According to Cognitive Market Research, the global systemic amyloidosis market size was estimated at USD 4256.5 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 212.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil systemic amyloidosis market size was valued at USD 91.09 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period because of the growing number of elderly people.
• Argentina's systemic amyloidosis market had a market share of USD 35.75 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period as a consequence of developments in medical technology.
• Colombia systemic amyloidosis market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 18.94 million in 2024.
• Peru systemic amyloidosis market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 17.45 million in 2024.
• Chile systemic amyloidosis market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 15.32 million in 2024.
• The Rest of Latin America's systemic amyloidosis market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 34.26 million in 2024.

Middle East Systemic Amyloidosis

According to Cognitive Market Research, the global systemic amyloidosis market size was estimated at USD 4256.5 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 85.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031..

• The GCC Countries systemic amyloidosis market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 36.44 million in 2024 because to supportive government initiatives, higher spending, and better infrastructure for the healthcare industry.
• The Egypt systemic amyloidosis market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 8.94 million in 2024.
• The South Africa systemic amyloidosis market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 13.45 million in 2024 as a result of an increase in research and development efforts.
• The Turkey systemic amyloidosis market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 7.32 million in 2024.
• The Nigeria systemic amyloidosis market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 8.94 million in 2024.
• The Rest of MEA systemic amyloidosis market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 10.05 million in 2024.

Systemic Amyloidosis Market Analysis

Systemic Amyloidosis Market Type Segment Analysis

According to Cognitive Market Research, primary systemic amyloidosis (PSA) stands out as the dominant category over the projected period propelled by developments in tailored treatments and early diagnosis. PSA, often referred to as AL amyloidosis, is brought on by immunoglobulin light chains that are deposited by aberrant plasma cells. Early and more precise PSA detection has been made possible by recent advancements in diagnostic technologies, including sensitive biomarkers and sophisticated imaging. Furthermore, better treatment outcomes for PSA patients have been achieved by the introduction of innovative therapeutic drugs, such as proteasome inhibitors and monoclonal antibodies.

Secondary systemic amyloidosis emerges as the fastest-growing category in the systemic amyloidosis market, often referred to as AA amyloidosis, is impacted by the frequency of long-term inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and persistent infections. The accumulation of serum amyloid A protein, an acute-phase reactant created in reaction to persistent inflammation, causes AA amyloidosis. The diagnosis and treatment of AA amyloidosis are receiving more attention due to the increased prevalence of these underlying inflammatory disorders and the better management of associated symptoms.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Systemic Amyloidosis Industry. Request a Free Sample PDF!

Systemic Amyloidosis Market Application Segment Analysis

According to Cognitive Market Research, the dominant category is hospitals. In order to diagnose, treat, and manage systemic amyloidosis, hospitals are essential. Hospitals are investing in state-of-the-art diagnostic and therapeutic techniques as a result of the rising demand for specialist medical services and sophisticated treatment choices brought on by the disease's rising prevalence. Hospitals with multidisciplinary teams made up of hematologists, cardiologists, nephrologists, and other experts are necessary to give patients with amyloidosis thorough care.

The fastest-growing category in the systemic amyloidosis market is research institutes. The market for systemic amyloidosis is mostly driven by innovation and improvements that research organizations facilitate. These organizations are leading the way in the development of tailored medicines, the identification of new biomarkers, and enhanced diagnostic methods. The goal of ongoing research is to gain a better understanding of the pathophysiology of amyloidosis, which is essential for creating efficient treatments. The partnership between pharmaceutical corporations and research institutes expedites clinical implementation of scientific discoveries.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion